Oral Iron For Treating Anemia Using Nanotechnology

描述(申请人提供)：缺铁是慢性肾脏疾病(CKD)患者和许多其他人群经常遇到的问题。目前的口服铁剂耐受性很差。注射用铁制剂难以管理，价格昂贵，而且严重 不良反应。因此，需要一种高吸收、耐受性好的口服铁剂来治疗慢性肾脏疾病(CKD)相关的贫血，以补充红细胞生成刺激剂。我们的铁替代剂将具有以下特性：1)口服给药，不良反应最少；2)高效的肠道转运，血管系统进入；3)肝脏靶向，将铁释放到正常的铁库；4)成本效益高的制造，为医疗经济节省开支。我们的第一阶段SBIR应用程序旨在合成符合这一描述的原型产品。这将通过应用该公司的纳米技术专业知识来开发一种稳定的氧化铁胶体来实现，该胶体具有表面涂层，允许肠道运输，同时防止肠道内的细菌繁殖。我们建议的产品有望成为第一个商业上可行的口服铁替代疗法，患者可以安全地自我给药。

DESCRIPTION (provided by applicant): Iron deficiency is frequently encountered in chronic kidney disease (CKD) patients and many other populations. Current oral iron formulations are poorly tolerated. Injectable iron preparations are difficult to administer, costly and have serious adverse reactions. Therefore, a highly absorbable, well tolerated oral iron supplement for the treatment of anemia associated with chronic kidney disease (CKD) is needed to complement erythropoiesis-stimulating agents. Our iron replacement agent will have the following attributes: 1) oral delivery with minimal adverse events, 2) efficient intestinal transit with vascular system entry, 3) liver targeting where the iron is released to normal iron stores and 4) cost-effective manufacture providing savings to the medical economy. Our Phase I SBIR application is designed to synthesize prototype products fitting this description. This will be accomplished by applying the company's nano-technology expertise to develop a stable iron oxide colloid having a surface coating to permit intestinal transport while protecting against bacterial bloom within th gut. Our proposed product is expected to be the first commercially feasible oral iron replacement therapy that can be safely self-administrated by the patient.